News: Sun Pharmaceutical Industries Ltd (SUN.BO)

SUN.BO on Bombay Stock Exchange

811.20INR
26 Dec 2014
Price Change (% chg)

Rs6.50 (+0.81%)
Prev Close
Rs804.70
Open
Rs807.00
Day's High
Rs812.65
Day's Low
Rs804.00
Volume
84,807
Avg. Vol
192,502
52-wk High
Rs932.00
52-wk Low
Rs552.50

Search Stocks
Select another date:

Mon, Dec 8 2014

Deals of the day- Mergers and acquisitions

(Adds Mizuho, Oriola-KD, Sharp, Vattenfall, TriMas Corp, Abris Capital)

CORRECTED-Deals of the day- Mergers and acquisitions

(Removes erroneous reference to Canadian Solar in Sharp Corp item)

UPDATE 1-India's Ranbaxy books first profit in 6 quarters on exclusive drug launch

* Shares rise 6 pct, outpacing market (Adds details on results, shares, context)

Merck licenses experimental psoriasis drug to India's Sun Pharma

- Merck & Co Inc said it had licensed its experimental psoriasis drug to Indian generic maker Sun Pharmaceutical Industries Ltd for $80 million.

India regulator says Sun's takeover of Ranbaxy may hurt competition

MUMBAI - India's antitrust regulator said on Thursday it had made an initial observation that Sun Pharmaceutical Industries Ltd's agreed $3.2 billion acquisition of Ranbaxy Laboratories Ltd could hurt competition, asking the companies to provide more details.

India regulator says Sun's takeover of Ranbaxy may hurt competition

MUMBAI, Sept 4 - India's antitrust regulator said on Thursday it had made an initial observation that Sun Pharmaceutical Industries Ltd's agreed $3.2 billion acquisition of Ranbaxy Laboratories Ltd could hurt competition, asking the companies to provide more details.

India's Ranbaxy Laboratories posts loss in June quarter

MUMBAI, July 29 - Indian drugmaker Ranbaxy Laboratories Ltd, which has agreed to be acquired by local rival Sun Pharmaceutical Industries Ltd, posted a net loss in the June quarter hit by a one-time provision.

India's Sun Pharma acquires U.S.-based Pharmalucence

MUMBAI, July 16 - Sun Pharmaceutical Industries Ltd, India's third-largest generic drugmaker by sales, said on Wednesday it had acquired U.S.-based Pharmalucence Inc, which has sterile injectable capacity and research capabilities.

Select another date:
Search Stocks